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A B S T R A C T
Introduction: Home fortiﬁcation powders containing iron and other micronutrients have been recommended by
World Health Organisation to prevent iron deﬁciency anaemia in areas of high prevalence. There is evidence,
however, that home fortiﬁcation at this iron dose may cause gastrointestinal adverse events including diarrhoea.
Providing a low dose of highly absorbable iron (3 mg iron as NaFeEDTA) may be safer because the decreased
amount of iron in the gut lumen can possibly reduce the burden of these adverse eﬀects whilst resulting in
similar or higher amounts of absorbed iron.
Objective: To show non-inferiority of home fortiﬁcation with 3 mg iron as NaFeEDTA compared with 12.5 mg
iron as encapsulated ferrous fumarate, with haemoglobin response as the primary outcome.
Design: 338 Kenyan children aged 12–36 months will be randomly allocated to daily home fortiﬁcation with
either: a) 3 mg iron as NaFeEDTA (experimental treatment), b) 12.5 mg iron as encapsulated ferrous fumarate
(reference), or c) placebo. At baseline, after 30 days of intervention and within 100 days post-intervention, blood
samples will be assessed for primary outcome (haemoglobin concentration), iron status markers, Plasmodium
parasitaemia and inﬂammation markers. Urine and stool samples will be assessed for hepcidin concentrations
and inﬂammation, respectively. Adherence will be assessed by self-reporting, sachet counts and by an electronic
monitoring device.
Conclusion: If daily home fortiﬁcation with a low dose of iron (3 mg NaFeEDTA) has similar or superior eﬃcacy
to a high dose (12.5 mg ferrous fumarate) then it would be the preferred choice for treatment of iron deﬁciency
anaemia in children.
1. Introduction
Home fortiﬁcation aims at supplementing local diets by adding
micronutrient powders to semi-solid, ready-prepared foods (http://
www.hftag.org/). The World Health Organisation (WHO) recommends
daily universal home fortiﬁcation with iron for children aged 6–23
months in populations where the prevalence of anaemia in children
under 5 years of age is≥ 20% [1]. Prevalence values within this range
indicate a moderate-to-severe public health problem, which is the
situation in virtually all developing countries [2].
The WHO-recommended iron dose for home fortiﬁcation
(10–12.5 mg iron as ferrous salt for children aged 6–23 months, [1])
corresponds to the dose that was previously established for iron
supplementation in this age range [3]. There is evidence from
randomised controlled trials among young children in low-income
countries to suggest that home fortiﬁcation with iron-containing
micronutrients may cause an excess burden of diarrhoea, and increased
numbers of potentially pathogenic enterobacteria, with a concurrent
increase in gut inﬂammation [4]. Other gastrointestinal adverse eﬀects
of oral iron supplementation, such as epigastric discomfort, nausea and
constipation, are common, are dose-dependent and are likely to reduce
adherence [5].
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Compared to the conventional daily dose (12.5 mg as ferrous salt),
home fortiﬁcation or supplementation with a low dose of highly
absorbable iron (3 mg iron as NaFeEDTA) may result in similar or
higher amounts of absorbed iron [6,7] but the decreased amount of iron
in the gut lumen can possibly reduce the burden of adverse gastro-
intestinal eﬀects.
There is substantial evidence that iron interventions in young
children can also increase rates of malaria and possibly respiratory
disease [8–11]. Because adverse events associated with such systemic
diseases are likely to depend on the absorbed amount of iron, the risks
may be similar when comparing a daily dose of 3 mg iron as NaFeEDTA
and 12.5 mg as ferrous salt. WHO has recommended that iron
interventions should be implemented in conjunction with measures to
control malaria [1].
We aimed to show non-inferiority of home fortiﬁcation with 3 mg
iron as NaFeEDTA compared with 12.5 mg iron as encapsulated ferrous
fumarate in young Kenyan children protected for 3–4 weeks against
malaria by chemoprevention.
2. Study methodology
2.1. Study site
The study will be conducted from January–December 2014 in the
administrative units of Kanyawegi, Osiri and Ojolla in Kisumu-West
District, a rural area at an altitude below 1,300 m, adjacent to Lake
Victoria, Kenya. This area covers 395 square kilometres with a
population of approximately 12,000 people, of whom 20% are children
aged below ﬁve years. The majority of the population consists of
subsistence farming families but inadequate and unreliable rainfall
patterns have immensely aﬀected agricultural activities in the area
[12]. The local diet is mainly based on maize and vegetables. Animal
foods, which are rich sources of iron, are rarely consumed and often
sold in the urban markets to boost income. Malaria transmission is
perennial and stable [13], with most infections being due to Plasmodium
falciparum [14]. The prevalence of P. falciparum infection in children
aged 1–4 years has been reported to range between 39% and 63% [15].
The area is endemic for Schistosoma mansoni, with a prevalence of
infection in infants of 14% [16]. Hookworm and Trichuris trichiura
infections are also common in young children [17]. Co-infection of
hookworm, T. trichiura and P. falciparum has been associated with low
haemoglobin concentrations in pre-school children [18].
2.2. Study design
This study concerns a randomised, double-blind, non-inferiority
trial comparing daily home fortiﬁcation for 30 days with 3 mg iron as
NaFeEDTA (investigational intervention), 12.5 mg iron as encapsulated
ferrous fumarate (reference) and placebo. We conceived it as an
explanatory trial to evaluate the eﬃcacy of daily home iron fortiﬁcation
under maximal compliance.
2.3. Sample size determination
Sample size calculations are based on procedures for non-inferiority
trials as recommended by USA Food and Drug Administration [19,20].
1. Based on a meta-analysis [21] we estimated the expected eﬀect of
12.5 mg iron as ferrous fumarate on haemoglobin concentration
relative to placebo. The lower limit of the 95% CI thus obtained
(9.3 g/L) was used as M1, the minimum anticipated eﬀect of 12.5 mg
iron as ferrous fumarate (Fig. 1; left panel).
2. Next, we set M2 as the margin speciﬁed to preserve 50% of the
anticipated minimum eﬀect of 12.5 mg ferrous fumarate. This
margin (haemoglobin concentration of 4.7 g/L) can be interpreted
as the largest loss of eﬀect compared to 12.5 mg ferrous fumarate
(inferiority) that would be acceptable, and is below an eﬀect for 5 g/
L iron as NaFeEDTA that we considered to be of minimum
importance for public health.
3. We set the sample size at 339 children (estimating 113 children per
intervention group) so that the lower limit of the 95% CI around the
diﬀerence in haemoglobin concentration between the two iron
formulations (i.e. 12.5 mg ferrous fumarate and 3.0 mg iron as
NaFeEDTA) would lie above M2 (Fig. 1; right panel).
2.4. Recruitment
The research assistants will hold meetings with local authorities,
community health workers and parents to inform them about study
aims and procedures. The community health workers will compile a list
of parents with children aged 1–3 years residing within the three
administrative units, and invite parents to bring these children for
screening to the research clinic, where they will be asked to sign an
informed consent form (Appendices 1, 2).
At the screening visit, research assistants will collect vital data and
information on household characteristics: a) date of birth as recorded in
the birth certiﬁcate or health card held by the mother or, if not
available, from records of the Expanded Program of Immunization held
by local clinics; b) anthropometric data that include weight measured
to the nearest 100 g using a Salter scale (UNICEF, catalogue 0145555,
Copenhagen, Denmark) that is calibrated daily using a 5 kg weight.
During measurement, the child will wear neither clothes nor shoes;
standing height (children ≥24 months or ≥ 85 cm) or recumbent
length (children ≤24 months or ≤ 85 cm) will be measured within
0.1 cm using wooden measuring boards (UNICEF, catalogue 0114500);
and mid-upper arm circumference, a marker of wasting, using a
measuring tape (UNICEF, catalogue 145600) within 0.1 cm.
Medical staﬀ will conduct medical examinations and collect the
following data: a) a parent-reported 48-h history of illness including
fever, diarrhoea, vomiting or breathing distress; b) parent-reported
history of signs of major systemic disorders; c) parent-reported use of
speciﬁc medicines (antiretroviral drugs, rifampicin, carbamazepine,
phenytoin or phenobarbital); c) parent-reported drug allergies, or 30-
day history of using drugs (antimalarials, benzimidazoles, praziquantel)
that might interfere with the study treatment protocol.
Clinical oﬃcers will ask parents to bring children for re-screening
two weeks later if the child has a 48 h history of antimalarial drug use,
or has received treatment for malaria. Children with axillary tempera-
ture ≥37.5 °C plus demonstrated blood infection (rapid dipstick tests
positive for malaria) or minor illnesses will be treated immediately and
also asked to return after two weeks for re-screening.
Phlebotomists will collect venous blood (4 mL) in tubes containing
Li-heparin. We will determine haemoglobin concentration (HemoCue
301, Ängelholm, Sweden) and zinc protoporphyrin:haem ratio (AVIV,
model 206D, Lakewood NJ, USA) in whole blood as a marker of iron-
deﬁcient erythropoiesis, each in triplicate. We will assay Plasmodium
antigenaemia by rapid tests (see section ‘Laboratory analyses’ below).
We will transfer aliquots of whole blood (125 μL) to DNA collection
cards (FTA Mini Card, catalogue WB120055, Little Chalfont, UK) for
storage at ambient temperature and subsequent detection by PCR of
Plasmodium infection; and we will prepare thick and thin blood smears
to allow for detection and counting of Plasmodium parasites.
An aliquot (1.0 mL) of blood will be centrifuged (600 × g, 10 min).
Plasma (500 μL) will be transferred to a microtube, centrifuged
(2000–3000 × g, 15 min), transferred to a cryovial, and stored
immediately in liquid nitrogen (−196 °C). The erythrocyte sediment
(500 μL) will be washed and centrifuged (600 × g, 8 min) three times
with isotonic phosphate-buﬀered saline (Medicago, Uppsala, Sweden;
catalogue 09-9400-100) to allow measurement in triplicate of the
erythrocyte zinc protoporphyrin:haem ratio. Measurement of zinc
protoporphyrin:haem ratio in washed erythrocytes is considered a more
valid measurement when compared to whole blood because the
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washing process removes substances dissolved in the plasma such as
bilirubin that ﬂuorescence in the same wavelength range as ZPP [22].
An aliquot of washed erythrocytes will be transferred to a cryovial for
storage and subsequent measurement of folate concentration, and to a
cryotube preﬁlled with 0.9% saline solution and a lysing agent (Celite,
Sigma-Aldrich, catalogue 525235, St. Louis, MO) for subsequent acid
extraction and measurement of metal-free protoporphyrin.
The remainder of the blood (2.75 mL) will be centrifuged
(2000–3000 × g;>15 min); aliquots of plasma will be stored in liquid
nitrogen for subsequent measurement of iron markers (concentrations
of ferritin, soluble transferrin receptor) and inﬂammation indicators
(concentrations of C-reactive protein, α-1-acid glycoprotein). 125 μL
buﬀy coat will be pipetted on DNA collection cards (FTA Mini Card),
allowed to dry, stored and sealed in multi-barrier pouches containing
1 g desiccant for subsequent genotyping for host polymorphisms
associated with susceptibility to malaria.
Research assistants will collect urine samples at the research clinic
using 100 mL paediatric collection bags (Changzhou Huankang,
Changzhou, Jiangsu, China). Prior to urine collection, we will clean
and dry the area around the vulva or penis using disinfectant baby
wipes or soap and water, apply the urine bags, and re-apply the child's
diapers or pants. Parents will be asked to check regularly to ensure that
the child does not remove the urine bag, and to inspect if the child has
produced urine. Urine will be drained into a sterile 125 mL container.
Samples (2 mL) will be stored immediately in liquid nitrogen for
subsequent assessment of Schistosoma ova and hepcidin concentrations.
Research assistants will collect faecal samples at the research clinic
on an aluminium sheet placed either inside a child's potty or directly
onto the ﬂoor. Stool that is mixed with urine will be discarded. If a child
is unable to produce stool, the parent will be asked to bring him/her
again and retry on the subsequent 3 days until the stool is produced. A
scoop (10 mL) will be transferred using a plastic spatula into a sterile
disposable container that is placed immediately into a cool box and
taken to the laboratory, where aliquots (2 mL) will be stored in liquid
nitrogen for subsequent measurement of calprotectin concentration as
an indicator of intestinal inﬂammation, and to assess for intestinal
infections.
2.5. Premedication
Pre-medication will be administered to every eligible child during
screening visit. We will give a therapeutic course of dihydroartemisinin-
piperaquine (Sigma-tau, Rome, Italy; 40 mg dihydroartemisinin/
320 mg piperaquine, administered as a daily dose for 3 consecutive
days of ½ tablet and 1 tablet for children in weight ranges 7–12.99 kg
and 13–24 kg, respectively) with the aim to protect children against
malaria in the subsequent intervention period.
To protect against severe anaemia during the intervention period,
we will administer two antihelminth drugs at the research clinic as per
WHO recommendations [23]. Albendazole (Indoco Remedies, Mumbai,
India) will be administered for 3 days at a daily dose of 200 mg or
400 mg for children aged 12–24 months and>24–36 months, respec-
tively. Praziquantel (Cosmos, Nairobi, Kenya; 600 mg tablets) will be
administered as a single target dose of 40 mg per kg body weight
(< 10 kg: ½tablet; 10–12 kg: ¾ tablet; > 13 kg: 1 tablet). The clinical
oﬃcer will administer praziquantel and the ﬁrst dose of albendazole
and dihydroartemisinin-piperaquine at the research clinic, and instruct
parents to administer the remaining doses at home. Albendazole and
dihydroartemisinin-piperaquine will be given 1 h after consumption of
food, while praziquantel will be administered after child has consumed
a cup of uji (maize gruel, a common food locally given to young
children) or after lunch to avoid adverse eﬀects (e.g. nausea, vomiting,
and abdominal pain). The clinical oﬃcer will crush and mix the tablets
with clean drinking water and observe that the child swallowed them. If
a child vomits the medicine within a period of 10 min, a repeat dose
will be given immediately. The clinical oﬃcer will inform parents about
the reasons why their child should complete the remaining two drug
doses. Parents will be requested to observe any possible adverse
reactions and report immediately to the ﬁeld research workers. Parents
will also be asked not to give their children foods based on maize or
Fig. 1. Theoretical framework for sample size determination. The treatment eﬀects are shown as 95% CIs around the estimates (shown by the blue lines). The estimated margin values are
shown by the dotted red lines. Left panel: M1 is the lower bound of 95% Cl, estimated at 9.3 g/L and being the smallest eﬀect of the 12.5 mg iron as ferrous fumarate (reference
intervention) versus placebo. M2 – is the non-inferiority margin estimated as a 50% reduction of the minimum anticipated value eﬀect (9.3%g/L) of reference intervention which
corresponds to 4.7 g/L; Right panel: Success will be estimated as the diﬀerence in haemoglobin concentration between 12.5 mg ferrous fumarate and 3.0 mg iron as NaFeEDTA should lie
above M2, a conservative eﬀect considered to be of minimum public health relevance. Using 113 children per group, the trial had 90% probability to detect superiority of the
investigational arm over placebo and 95% probability showing non-inferiority relative to reference intervention given the following assumptions: eﬀect of 5 g/L; equal group SDs of 10 g/
L; 2-sided α = 0.05; maximally 5% of children will drop out of the iron group, no ‘drop-in’ will occur of children crossing over from the placebo group to the iron group.
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sorghum ﬂour 2–3-h before returning to the research clinic on the
scheduled return date.
2.6. Eligibility criteria
We will include children if aged 12–36 months; resident in the study
area and whose parents intended to stay in the area in the subsequent
nine months; parental consent form signed by both parents; not acutely
sick or febrile (axillary temperature≥37 °C) at the time of recruitment;
absence of reported or suspected major systemic disorder (e.g. HIV
infection, sickle cell disease); no use of antiretroviral drugs against HIV,
rifampicin, carbamazepine, phenytoin or phenobarbital; no twin sib-
ling. Children will be excluded if: haemoglobin concentration< 70 g/L;
severely wasted (weight-for-height z-score< ‒3 SD); known allergy to
dihydroartemisinin-piperaquine, benzimidazoles or praziquantel; par-
ent-reported history of using antihelminthic drugs in the 1-month
period before the screening date; not at risk of malaria (e.g. children
who received chemoprophylaxis against malaria because of HIV infec-
tion or sickle cell disease); after three days parent-reports child has not
completed the 2nd and 3rd doses of dihydroartemisinin-piperaquine
and benzimidazoles; has adverse eﬀects associated with pre-medica-
tion; has fever (axillary temperature ≥37 °C); presents with any other
illness.
2.7. Randomisation
To achieve group balance in size and baseline haemoglobin
concentration, randomisation will be based on a stratiﬁed block design.
A person not involved in the ﬁeld work will create the randomisation
scheme by assigning three treatment groups in a sequence of random
permuted blocks of sizes 6 or 9 within two strata deﬁned by baseline
haemoglobin concentration class (< 100 g/L and ≥100 g/L), using
tables with random numbers and random permuted blocks. Using this
scheme, two other persons not involved in the ﬁeld work will produce a
set of labels with a child identiﬁcation number that includes a letter for
stratum (A or B) and a consecutive allocation number as indicated by
the randomisation scheme. These labels will be stuck on a) sealed
opaque envelopes each containing a paper slip with the word ‘iron’ or
‘placebo’; and b) plastic bottles, each containing 30 sachets of one of the
three types of micronutrient powders (see ‘Interventions’, below). The
bottles will then be arranged in boxes according to stratum and
sequential number as indicated in the randomisation scheme and
handed over, together with the sealed envelopes, to the ﬁeld team.
All research staﬀ (including trial coordinator) will not be allowed to
open the envelopes until the end of the 30-day intervention period.
On the randomisation day visit, the trial coordinator will assign
children successively to the next available allocation number within the
appropriate stratum (indicated by haemoglobin concentration mea-
sured at the screening visit). This process will continue until the target
sample size has been attained.
2.8. Interventions
We will use three types of micronutrient powders manufactured
speciﬁcally for this trial by DSM Nutrition Products (Johannesburg,
South Africa) and that contain 1 g sachets with either 3 mg iron as
NaFeEDTA, 12.5 mg iron as encapsulated ferrous fumarate or without
iron (placebo). The encapsulate consists of a thin coat of soy lipid. All
powder types will contain thirteen micronutrients other than iron
(Table 1), as recommended by the Home Fortiﬁcation Technical
Advisory Group except for folic acid, which we will omit because of
our concerns that it may be utilized by Plasmodium parasites and
increase the failure risk of anti-folate drugs, and because there is no
evidence that folate deﬁciency is a public health problem among
children in developing countries [24]. At the randomisation visit,
research assistants will instruct parents on the use of the fortiﬁcants,
give them a supply of 30 sachets in a plastic bottle randomly assigned
for each child by the trial coordinator, and ask them to daily add the
contents of one sachet per child to semi-solid, ready-prepared foods for
a period of 30 days. The assistants will also show them how to mix the
content of the sachet (the ﬁrst dose) with uji.
2.9. Blinding
Each type of micronutrient powders will be packed in identical plain
white foiled sachets except for the batch number. Parents will receive
30 sachets for each child in a white plastic bottle that contains no other
marker except the label with stratum, allocation number, name, start
date and return date. The three types of micronutrient powders do not
have apparent diﬀerences in taste, texture or colour of uji. Research
assistants will observe consumption of each cup of uji during the
administration of the ﬁrst dose of treatment at the research clinic.
Researchers, outcome assessors and parents will remain fully blinded to
allocation and intervention until the 30-day intervention period has
been completed. At that time, the trial coordinator will open the sealed
envelopes to determine whether a child had received iron or placebo.
Because the information in the envelope will not reveal the type of iron
group, research assistants will be partially de-blinded; full de-blinding
will be done after the statistical analysis plan has been completed and
after crude intervention eﬀects have been analysed without identiﬁca-
tion of the iron interventions.
2.10. Adherence monitoring
Adherence to intervention will be primarily monitored using an
electronic monitoring and time-recording device (MEMS 6 TrackCap
45 mm without LCD display; http://www.mwvaardex.com/) that will
be given for the duration of the study to parents of participating
children. This battery-operated device consists of a cap that ﬁts the
bottle containing the micronutrient sachets, with a built-in micropro-
cessor that records and stores date and time of all closings. Adherence
assessment using these devices is considered the reference standard
[25,26] and superior to medication counts and self-reported adherence,
which are commonly used methods that tend to result in over-estimates
[27,28]. Each bottle will be labelled with a child's identiﬁcation
number, serial number of the cap, name of child, start date and end
date for ease of identiﬁcation and tracking. Except for the trial
coordinator and one ﬁeld supervisor, neither parents nor research
assistants will be informed about the function of the electronic device.
Instead they will be informed that the MEMS cap is essential for
maintaining the moisture content and good hygienic conditions of the
micronutrient powder. Parents will be thoroughly instructed to close
Table 1
Formulation of micronutrient powders.
Micronutrient Content
Vitamin A, μg RE 300
Vitamin D, μg 5
Vitamin E, mg 5
Vitamin C, mg 30
Thiamin (vitamin B1), mg 0.5
Riboﬂavin (vitamin B2), mg 0.5
Niacin (vitamin B3),mg 6
Vitamin B6 (pyridoxine), mg 0.5
Vitamin B12 (cobalamine), μg 0.9
Iron
EITHER iron as encapsulated ferrous fumarate, mg 12.5
OR iron as NaFeEDTA, mg 3
OR no iron (placebo) 0
Zinc, mg 5
Copper, mg 0.56
Selenium, μg 17
Iodine, μg 90
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the bottle after each opening, and will be shown how to use the storage
bottle with the MEMS cap. In addition, parents will be requested to
keep empty sachets in a zip-lock plastic bag marked with the child's
name and identiﬁcation number. These bags will be collected at the end
of the study to allow adherence assessment by sachet count.
Parents will be taught how to ﬁll out self-reporting forms written in
their local language (Dholuo), and requested to daily record (by a tick)
when the fortiﬁcant-containing food is given (morning, mid-morning,
lunch, mid-afternoon or evening) during the 30-day intervention
period. Lastly, parents will be instructed about the importance of
immediately reporting any sickness or adverse reactions experienced
by the child during the 30 days, and the date of reporting back to the
research clinic.
2.11. Assessment of non-transferrin bound iron (NTBI)
Three hours after administering the ﬁrst dose of home fortiﬁcants
with uji, we will collect capillary blood (400–500 μL) by ﬁnger puncture
in tubes without anticoagulant (Becton Dickinson, Breda, The
Netherlands), using vinyl gloves to avoid contamination with trace
elements, and avoiding ﬁnger squeezing. After clotting (30 min), serum
will be transferred to a microtube, centrifuged (6000–15,000 × g,
10 min), and aliquots (300 μL) transferred to cryovials and stored in
liquid nitrogen for subsequent NTBI analysis.
2.12. Follow-up during 30-day intervention period
Fig. 2 provides an overview of data and samples that will be
collected in the course of the trial. Field workers will conduct weekly
pre-announced home visits to check if the child is still in the study area,
if parents are following protocol when administering the fortiﬁcants,
and if parents are ﬁlling out forms and storing empty sachets. During
these visits, ﬁeld workers will discuss problems or clarify procedures,
but they will not give parents instructions additionally to those given
during the randomisation visit. All observations and problems experi-
enced by parents will be recorded in a form and submitted to the ﬁeld
supervisor at the end of each day. Sick children will be referred to the
research clinic. Clinicians and laboratory technicians will be available
24 h per day. Children with severe illness or serious adverse events will
be referred to a nearby referral hospital (Kisumu town), and taken
either by project vehicle or by local transport with refund of transport
fees. Parents who withdraw children from the intervention will be
asked for reasons and for permission to keep and analyse data and
samples already collected.
2.13. Survey at 30 days of intervention
Parents will be asked to bring their children to the research clinic at
30 days post-randomisation. During this visit, clinicians will perform a
medical examination and research assistants and phlebotomists will
collect anthropometric data and samples (blood, urine and stool) as
described for screening. Parents will be asked to return the plastic
bottles with the MEMS cap, empty sachets and the self-reporting form.
We will count the number of sachets and download information from
the electronic device onto a computer. In addition, we will administer a
standardised questionnaire to collect information on possible factors
aﬀecting adherence. Once all data and samples are collected, the trial
coordinator will open the sealed brown envelope to determine child's
intervention group (iron or placebo).
2.14. Post-intervention period
Children who received placebo will be retained in the study to
observe adherence to home fortiﬁcation during another 30-day period
in the absence of regular monitoring visits by research assistants. Thus
they will be given a 3-day therapeutic course of dihydroartemisinin-
piperaquine and 30 sachets of 12.5 mg encapsulated ferrous fumarate in
a bottle with the MEMS cap and again receive self-reporting forms, and
instructions for use. Research assistants will conduct sporadic but pre-
announced visits to their homes (one visit per child and additional visits
as needed for a child with adverse events) to observe if the child is still
resident and follows protocol and to check for sickness or adverse
reactions. At the end of the 30-day post-intervention period, parents
will be asked to returned to the clinic to submit the bottle with the
Fig. 2. Data collection timelines.
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MEMS cap, self-reporting forms and empty sachets. Children will be
medically examined, treated for incident illness as appropriate, and exit
the study.
Children allocated to the iron group will not be given fortiﬁcation
powders but instead will be retained in the study to monitor the
population decline in haemoglobin concentration over time in a 100-
day follow-up period. During this period, haemoglobin concentrations
are expected to decline exponentially (i.e. at a rate that is proportional
to its current value), up to a point when it would be theoretically
desirable to retreat the group with a new cycle of therapeutic course of
antimalarial drugs with iron fortiﬁcation. We aim to estimate the time
point when ≥10% of children has developed severe anaemia haemo-
globin concentration< 70 g/L; [29], taking into account our wish to
restrict phlebotomies during the post-intervention period (for ethical
reasons) to a single occasion per child. Thus we will phlebotomise each
child on a single, randomly selected day in the 100-day follow-up
period. We will use pre-programmed MS Excel software to randomly
select a date of their return visit within a 100-day period. The date of
this return visit will be concealed in the MS excel program until after
the 30-day intervention return visit. Once the date is randomly
calculated by the software, parents will be asked to take each child
home and return on the randomly selected date. Parents will be
requested to report immediately any sickness or adverse reactions
experienced by the child during the post intervention period.
On the return visit, a laboratory assistant will collect capillary blood
by ﬁnger puncture to measure haemoglobin concentrations in duplicate
from a single drop, and to store DNA on a FTA Mini Card for subsequent
assessment by PCR assay of Plasmodium parasites. Immediately follow-
ing phlebotomy, half of these children will be withdrawn from further
study (for ethical reasons) and will be given a therapeutic course of
dihydroartemisinin-piperaquine and a supply of sachets for daily home
fortiﬁcation with 12.5 mg iron as encapsulated ferrous fumarate stored
in silver blister pockets for another 30 days. The other half will be given
a therapeutic course of dihydroartemisinin-piperaquine and a supply of
sachets for daily home fortiﬁcation with 12.5 mg iron as encapsulated
ferrous fumarate in bottles with MEMS cap and a reporting format to
determine the eﬀect of interrupted fortiﬁcation on adherence. These
children will be requested to visit the research clinic after 30 days, the
parents will be interviewed and informed on the three adherence tools
processed similar to the end of 30-day intervention period. A summary
of the ﬂow of activities for the post intervention period is presented in
Fig. 3.
2.15. Laboratory analyses
We will use two rapid tests (AccessBio, Somerset, NJ; CareStart
G0151 and G0171) to detect P. falciparum-speciﬁc histidine-rich protein
2, P. falciparum-speciﬁc lactate dehydrogenase (LDH), and LDH speciﬁc
for human Plasmodium spp. other than P. falciparum. The pLDH-based
test was used to detect current infection [30–32]. We will use two
commercially available tests (Hemoccult SENSA, Clindia Benelux,
Almere, The Netherlands, catalogue no. 20000702; FOB advanced+,
Ulti Med, Roeselare, Belgium, catalogue 010A210-20) to detect the
presence of faecal occult blood, following assay instructions given by
the manufacturers. Faecal occult blood will be interpreted as evidence
of intestinal bleeding due to gastrointestinal helminths. Iron markers
(plasma concentrations of ferritin, soluble transferrin receptor, trans-
ferrin), inﬂammation markers (plasma concentrations of C-reactive
protein [CRP] and α1-acid glycoprotein), albumin and vitamin B12 will
be measured on an Abbott Architect C16000 and i2000 SR analyser as
per manufacturer's instructions.
2.16. Study outcomes
We will use the following outcome deﬁnitions: anaemia: haemoglo-
bin concentration<110 g/L; mild, moderate and severe anaemia:
haemoglobin concentration 100–109 g/L, 70–99 g/L and<70 g/L,
respectively [29]; iron status: deﬁcient (plasma ferritin concentration <
12 μg/L), replete (plasma ferritin concentration ≥ 12 μg/L in the
absence of inﬂammation) or uncertain (plasma ferritin concentra-
tion ≥ 12 μg/L in the presence of inﬂammation) [33]; iron deﬁciency
anaemia: concurrent anaemia and iron deﬁciency; inﬂammation: plasma
concentrations of C-reactive protein and/or α1-acid glycoprotein of>
5 mg/L [34] and>1.0 g/L [35], respectively; Plasmodium infection:
presence or absence of parasites as indicated by histidine-rich protein-2,
lactate dehydrogenase speciﬁc for P. falciparum or human Plasmodium
spp. other than P. falciparum (i.e. P. vivax, P. malariae or P. ovale); high,
medium and low Plasmodium parasite density: parasitaemia ≥10,000/
μL, 1000–9999/μL and< 1000/μL, respectively. We will deﬁne high
adherence (≥80%, 24 days or more) and low adherence (< 80%, 23
days or less) of scheduled fortiﬁcation powders, as indicated by the
MEMS device. This threshold is arbitrary, but is often used in published
studies on medication adherence [28,36–39].
2.17. Statistical analysis
A statistical analysis plan will be ﬁnalised after data collection but
before breaking the randomisation code.
Anthropometric indices will be calculated using WHO Anthro
software vs.3.2.2 (World Health Organisation, Geneva, Switzerland).
Data analysis will be done using SPSS 21 (IBM, Armonk, NY), CIA 2.2.0
(http://www.som.soton.ac.uk/research/sites/cia/), R software version
3.2.0 (www.r-project.org), and PowerView vs.3.5.2 (AARDEX Group
ltd, Sion Switzerland; to analyse electronic adherence data). Since this
is perceived to be an explanatory trial and as per recommendations by
the European Medicine Agency for non-inferiority trials [40], we will
pursue the primary (non-inferiority) objective by comparing results
obtained by both intention-to-treat analysis and per protocol analysis,
without formal adjustment for multiplicity (further details in discussion
section).
Proportions and group means will be compared by conventional
methods and expressed as absolute diﬀerences with corresponding 95%
CIs; and with log-transformations as appropriate. We will estimate
eﬀects when possible; P-values, where reported, will be 2-sided. For
primary analysis, we will estimate the diﬀerence in haemoglobin
concentrations at the end of the 30-day fortiﬁcation period between
groups of children allocated to diﬀerent iron formulations. Non-
inferiority will be rejected if the diﬀerence between groups is less than
the non-inferiority margin of 4.7 g/L.
2.18. Data and safety monitoring
We will appoint a trial monitor and an independent data and safety
monitoring committee to review un-blinded data for safety purposes,
monitor the progress of the trial, and to assess whether there were any
safety issues that should be brought to participants' attention. No
interim analyses will be conducted.
2.19. Ethical clearance
Ethical clearance has been obtained from London School of Hygiene
and Tropical Medicine Ethical Committee, UK (6503) and the Kenyatta
National Hospital/University of Nairobi Ethical Review Committee,
Kenya (KNH-ERC/A/402). The trial is registered with ClinicalTrials.gov
(NCT02073149).
3. Discussion
3.1. Duration of the intervention
We selected a relatively short 30-day intervention with iron in the
expectation that premedication with dihydroartemisinin-piperaquine
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will prevent malaria during this period, with a long-term view that the
protection aﬀorded by repeated chemoprevention with this combina-
tion drug would allow time windows for safe administration of short
courses of iron intervention. In a recent study among preschool children
in Burkina Faso, two cycles of chemoprevention with dihydroartemisi-
nin-piperaquine, administered at the same target dose as in our study,
resulted in a protection against malaria that persisted at a high level for
3–4 weeks and decreased rapidly thereafter, indicating that protection
lasts at most 3–4 weeks [41]. In an earlier placebo-controlled rando-
mised trial among Kenyan children aged 2–36 months, it was shown
with smaller sample size (79 iron; 76 placebo) than the present study
that weekly supplementation with 6 mg elemental iron as ferrous
fumarate per kg bodyweight improved haemoglobin concentration at 4
weeks after the start of intervention [42].
3.2. Justiﬁcation for use of a placebo
The use of placebo in non-inferiority trials is controversial.
Opponents have argued that: a) the use of placebos as controls is
unethical and mostly disregard the interest of patients [43]; b) placebo
group are unnecessary where there is proof of the eﬀect of the existing
treatment and as such any new treatment should be tested against the
existing treatment [44] and c) its use in trials should decline as medical
knowledge increases [45].
Inclusion of a third arm (placebo) in this trial adheres to the
guidelines for non-inferiority trials as stipulated by the European
Medicine Agency [40] and the International Conference on Harmonisa-
tion of Technical Requirements for Registration of Pharmaceuticals for
Human Use [46]. We perceive a placebo arm to be ethical in the
presence of an active control because in our study area there is no
national policy for preventive, community-based supplementation or
home fortiﬁcation with iron in children and yet the children under ﬁve
year are at a greater risk of iron deﬁciency anaemia. Because there is an
on-going uncertainty about the safety of iron interventions in children
living in malaria-endemic areas, our trial represents the only chance for
eligible children to receive fortiﬁcants of iron with micronutrients for
the iron arms and fortiﬁcants of micronutrients for the placebo arm
with malaria chemoprevention. Thus prohibition of the trial on ethical
grounds would be against the interest of eligible children and their
guardians.
Use of a placebo is necessary in our explanatory trial because we
aim to demonstrate that the experimental treatment (3 mg iron as
NaFeEDTA) is non-inferior to the active control (12.5 mg iron as
encapsulated ferrous fumarate). The demonstration of non-inferiority in
a trial with only two arms can have two meanings only: both
interventions are equally eﬀective, or both interventions are equally
ineﬀective against placebo. Furthermore, a placebo matches the
comparative treatments in all ways except for the therapeutic compo-
nents, and therefore the use of a standard treatment alone may not
necessarily control for the same set of non-speciﬁc factors as a placebo
[47]. Overall, the placebo group is useful for a) demonstration of
superiority of home fortiﬁcation with 3 mg iron as NaFeEDTA over
Fig. 3. Post intervention ﬂow of activities.
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placebo (proof of eﬃcacy); b) demonstration of superiority of the
reference (12.5 mg iron as encapsulated ferrous fumarate) over placebo
(proof of assay sensitivity) c) demonstration that home fortiﬁcation
with 3 mg iron as NaFeEDTA retains most of the eﬃcacy of the
reference over placebo (proof of non-inferiority) because failure for a
test drug to demonstrate eﬀectiveness does not necessarily mean it is
not eﬃcacious.
Increased medical knowledge has mistakenly been used to justify
dropping the use of placebo in trials; conversely, increased medical
knowledge has subsequently propell the production of new treatments.
Thus dropping the use of placebos in a trial limits the determination of
eﬃcacy and safety of the new treatment [48] consequently denying
physicians' opportunities to apply treatment options when needed.
3.3. Adjusting for multiplicity
It has been suggested that multiplicity adjustments may be neces-
sary in non-inferiority tests especially in studies with multiple objec-
tives [49]. European Medicine Agency regulatory guidelines [40]
clearly state that when interpreting a non-inferiority trial for a
potentially superior outcome there is no need to do multiplicity
adjustment because a statistical signiﬁcance test must be done to reject
the non-inferiority. In line with these regulatory guidelines for non-
inferiority trials we will not adjust for multiplicity for various reasons;
ﬁrst, our study has only one pre-deﬁned primary variable (haemoglobin
concentration at the end of the 30-day intervention period) that will be
used to demonstrate the treatment eﬀect. Second, as outlined in the
preceding section, all three comparisons of treatment eﬀects must show
statistical signiﬁcance of the haemoglobin concentration. We will
therefore conduct multiple regression analysis to investigate evidence
for group diﬀerences in the intervention eﬀects and to determine the
extent of bias due to irregularities between end points, because we
believe that results from multiple comparisons should be mutually
reinforcing, not mutually debasing [50] and hence no need for multi-
plicity adjustments. Third, any absence of treatment eﬀect diﬀerences
will be interpreted by conﬁdence interval in the context of the set
threshold for haemoglobin concentration (at a pre-set margin of 4.7 g/
L) and all reported p-values will be 2-sided. The use of conﬁdence
intervals and statistical tests are of an exploratory nature and therefore
no justiﬁcation for a claim is anticipated. In addition, any multiple
secondary endpoints analysis will provide supportive evidence related
to our primary objective (proof of eﬃcacy) and therefore no conﬁrma-
tory conclusions are necessary. Fourth, non-inferiority will be rejected
if the haemoglobin concentration diﬀerences between groups are less
than the already set margin of 4.7 g/L and the results show statistical
signiﬁcance; thus the rest of the secondary outcomes will be considered
supportive [51,52]; as such formal adjustments for the type 1 error will
be considered irrelevant.
4. Funding and role of the funding agencies
The trial is funded by Sight and Life, a non-proﬁt humanitarian
initiative established by DSM Chemicals, Heerlen, The Netherlands.
DSM Nutrition Products (Johannesburg, South Africa) manufactured
the supplements with micronutrient powders. The International
Nutrition Group of the Medical Research Council supported ET through
a personal grant. Micronutrients other than iron will be included in the
home fortiﬁcants at the request of Sight and Life; the funder will have
no further role in study design, data collection and analysis, preparation
of the manuscript, or decision to publish.
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Appendix 1. Information brochure
We would like to invite you to take part in a research study. Before you
decide you need to understand why the research is being done and what it
would involve for you. Please take time to read the following information
carefully. Talk to others about the study if you wish. Ask us if there is
anything that is not clear or if you would like more information. Take time to
decide whether or not you wish to take part.
What is the purpose of the study?
We want to conduct a study to compare home fortiﬁcation with two
iron formulations. Many young children in Kenya have anaemia, a
disorder that is characterized by blood with a light red colour, instead
of a healthy dark red. The red pigment in blood is necessary to transport
oxygen from inspired air to muscle. Children with anaemia often feel
weak or tired, and may have diﬃculty learning. To prevent anaemia in
children, medical doctors often prescribe supplements that contain
12.5 mg iron in a speciﬁc form (ferrous salts). A new form of iron has
recently become available that can probably be given at lower doses,
because the body is better able to absorb this type of iron.
In our study, we will divide young children into three groups and
give each group a diﬀerent treatment. Group 1 will receive the form of
iron that has been used so far (12.5 mg iron as ferrous fumarate), Group
2 will receive the new form of iron (3 mg iron as sodium iron EDTA),
and Group 3 will receive no iron. The results will be compared to
determine if the new type of iron (3 mg iron as sodium iron EDTA) can
prevent anaemia, and to determine if it is equally as good as the form of
iron that has been used so far (12.5 mg iron as ferrous fumarate).
We will provide both forms of iron in sachets (little bags). Each day,
the mother should empty and mix the contents of a single sachet into
ready-prepared uji or some other type of food, before giving it to the
child. This should be repeated every day for a period of 30 days. The
child will be followed for some time afterwards.
Although iron is good to prevent anaemia, there are some concerns
that it may increase the risk of malaria. For this reason, we will treat
each child with a special medicine against malaria (dihydroartemisinin-
piperaquine) at the start of the study, before the ﬁrst dose of iron is
provided. This medicine will protect the child against malaria for the
time period in which the child will receive iron. In addition, all children
will be dewormed at the start using two drugs (albendazole and
praziquantel).
Do you have to participate?
We have asked you to take part because your child is within the age
range suitable for our study. In total, we want to study 324 children.
You can let your child join the study at your own free will, and
withdraw your child at any moment, with or without giving reasons. . If
you decide not to participate, or to withdraw from the study, this will
not aﬀect the normal care you receive in clinics or hospital elsewhere.
Read this information sheet and listen to our explanation of the
study. We will then ask you to sign a consent form to show you have
agreed to take part.
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What will happen to you if you take part?
Screening visit: Our staﬀ will invite you and your child to our
research clinic to tell you about the aims and procedures of the study. If
you agree for your child to participate, we will ask you to sign their
ﬁngerprint on a consent form. To decide whether your child can
participate in the study, we will then ask you questions about your
child, we will carry out a medical examination, and we will then collect
samples of blood (6 mL, a volume equal to one table spoon) by arm
prick, urine and stool from the child. This will take at least several
hours. We will ask you to stay until if the child has produced stool. If
necessary we will invite to and your child again the next day to try
again. After sample collection, your child will be administered medi-
cines (albendazole, praziquantel against worms, and dihydroartemisi-
nin-piperaquine against malaria). You will be asked to bring your child
again to the research clinic 3 days later.
Randomisation visit: At this visit, we will use the information
collected so far to decide if your child can take part in the rest of the
study. Participating children will receive sachets with powder. These
sachets will be contained in a special dispensing bottle that you will
receive with instructions for use. For one-third of children, these
sachets will contain 12.5 mg iron as ferrous fumarate, one-third will
contain 3 mg iron as sodium iron EDTA, and one-third contains no iron.
For all three groups, the sachets also contain a mixture of other
vitamins and minerals that are important for health. The allocation to
group will be decided by chance (randomly). All sachets will look
identical; we will not know which supplements contain iron until after
the study. The ﬁrst sachet will be given with food at the research
dispensary. From 2 h before this point until 3 h afterwards, children
will be allowed to drink but can only eat foods selected by the project
team. We will then collect another blood sample (about 5–6 drops) by
ﬁnger prick. From then on, community volunteers will daily supervise
the supplementation in or close to your homestead.
During the 30-day intervention period: In the next 30 days, you should
add and mix the contents of a single sachet to uji or any other food
given to the child. Community volunteers will visit your home at least
once a week to answer questions that you may have about the study.
Children who become sick during this 30-day period will be referred to
receive routine care by the regular health services. You may decide to
withdraw your child at any point from the study. You may refuse to
give reasons for your refusal, or to give permission for future collection
of samples.
End-of-intervention survey: At the end of the 30-day period, we will
collect the dispensing bottle and ask you some questions. We will again
collect samples of blood (6 mL) by arm prick, stool and urine, using the
same procedures as earlier. For each child, we will then break the
randomisation code. Those who received placebo will be given
antimalarial medicines (dihydroartemisinin-piperaquine) and 30-day
supply of sachets with iron (12.5 mg iron as ferrous fumarate).
Follow-up after the 30-day intervention period: For children who
received placebo, ﬁeld staﬀ will collect the dispensing bottle with the
electronic device at the end of this 30-day period. Children who
received iron will continue to be followed for a maximum of 100 days.
In this period, we will collect a single sample of blood (5–6 drops, by
ﬁnger prick). The time point for this collection will be decided by
chance: for some children it may be as early as 1 week after home
fortiﬁcation was stopped; for others, it may be at the end of the 100-day
period. Immediately following blood collection, children will be with-
drawn from further study and will receive antimalarial medicines
(dihydroartemisinin-piperaquine) and 30-day supply of sachets with
iron (12.5 mg iron as ferrous fumarate). Field staﬀ will also collect the
dispensing bottle with the electronic device at this time.
To summarise, we will collect four blood samples from each child:
• Randomisation visit: 1 sample of 6 mL (a volume equal to one table
spoon), to be collected by arm prick;
• 3 h later: 1 sample of 5–6 drops, to be collected by ﬁnger prick;
• At the end of the 30-day period: 1 sample of 6 mL, to be collected by
arm prick;
• After the 30-day intervention period: 1 sample of 5–6 drops, to be
collected by ﬁnger prick.
We will store part of the blood samples in frozen condition, so that
we can subsequently conduct tests to assess the success of the
interventions. We may also check for hereditary factors that aﬀect
malaria and anaemia. Some of these tests may have to be done abroad.
Conﬁdentiality: Results of this study will be shared with the public in
a form of academic publication or presentation. The purpose of this
publication or presentation is to create awareness and promote under-
standing of safely and eﬃciently treating anaemia in malaria endemic
areas.
We will keep any information about your child conﬁdential. Readers
of the publication based on this research will not know that you gave
this information. All personal information will be stored securely. This
means that whenever we write or talk about anything we have been
told, we never use your real name. The only information that we may
have to pass on is if your child is at risk of serious harm.
Beneﬁts and compensation: You will not receive ﬁnancial beneﬁts for
participating in this study. If you need to stay more than 4 h, we will
give you a small ﬁnancial compensation to account for the lost hours.
References
[1] WHO Guideline: Use of Multiple Micronutrient Powders for Point-of-use
Fortiﬁcation of Foods Consumed by Infants and Young Children Aged 6–23 Months
and Children Aged 2–12 Years, World Health Organization, Geneva, Switzerland,
2016 Available at: http://apps.who.int/iris/bitstream/10665/252540/1/
9789241549943-eng.pdf?ua=1 (Accessed 6 February 2017).
[2] B. De Benoist, E. McLean, I. Egli, M. Cogswell (Eds.), Worldwide Prevalence of
Anaemia 1993-2005: WHO Global Database on Anaemia, World Health
Organization, Geneva, Switzerland, 2008Available at: http://apps.who.int/iris/
bitstream/10665/43894/1/9789241596657_eng.pdf (Accessed 6 February 2017).
[3] P. Nestel, D. Alnwickfor the International Nutritional Anaemia Consultative Group
(INACG), Iron/multi-micronutrient Supplements for Young Children: Summary and
Conclusions of a Consultation Held at UNICEF, Copenhagen, August 19–20, 1996,
ILSI Human Nutrition Institute, Washington DC, USA, 1997 Available at: http://
ilsirf.org/wp-content/uploads/sites/5/2016/04/INACG_Iron_Multi-Micronutrient_
Supplement-for-Young-Children.pdf (Accessed 6 February 2017).
[4] D. Paganini, M.A. Uyoga, M.B. Zimmermann, Iron fortiﬁcation of foods for infants
and children in low-income countries: eﬀects on the gut microbiome, gut
inﬂammation, and diarrhea, Nutrients 8 (8) (2016) 494.
[5] WHO, UNICEF, UNU, Iron Deﬁciency Anaemia: Assessment, Prevention, and
Control. A Guide for Programme Managers. Document Reference WHO/NHD/01.3,
World Health Organization, Geneva, 2001 Available at: http://apps.who.int/iris/
bitstream/10665/66914/1/WHO_NHD_01.3.pdf?ua=1 (Accessed 6 February
2017).
[6] B. Troesch, I. Egli, C. Zeder, R.F. Hurrell, S. de Pee, M.B. Zimmermann,
Optimization of a phytase-containing micronutrient powder with low amounts of
highly bioavailable iron for in-home fortiﬁcation of complementary foods, Am. J.
Clin. Nutr. 89 (2) (2009) 539–544.
[7] H. Verhoef, J. Veenemans, Safety of iron-fortiﬁed foods in malaria-endemic areas,
Am. J. Clin. Nutr. 89 (6) (2009) 1949–1950.
[8] S. Sooﬁ, S. Cousens, S.P. Iqbal, T. Akhund, J. Khan, I. Ahmed, A.K. Zaidi, et al.,
Eﬀect of provision of daily zinc and iron with several micronutrients on growth and
morbidity among young children in Pakistan: a cluster-randomised trial, Lancet 382
(9886) (2013) 29–40.
[9] World Health Organization Secretariat on behalf of the participants of the
Consultation, Conclusions and recommendations of the WHO Consultation on
prevention and control of iron deﬁciency in infants and young children in malaria-
endemic areas, Food Nutr. Bull. 28 (4 Suppl) (2007) S621–S627.
[10] J. Veenemans, P. Milligan, A.M. Prentice, L.R. Schouten, N. Inja, A.C. van der
Heijden, et al., Eﬀect of supplementation with zinc and other micronutrients on
malaria in Tanzanian children: a randomised trial, PLoS Med. 8 (11) (2011)
e1001125.
[11] M.M. Goheen, R. Wegmüller, A. Bah, B. Darboe, E. Danso, M. Aﬀara, et al., Anemia
oﬀers stronger protection than sickle cell trait against the erythrocytic stage of
falciparum malaria and this protection is reversed by iron supplementation,
EBioMedicine 14 (2016) 123–130.
[12] Government of Kenya (GoK). Kisumu district strategic plan 2005-2010 for
implementation of the national population policy for sustainable development.
[13] Government of Kenya (GoK), Ministry of Public Health and Sanitation, Malaria
indicator survey (KMIS) report 2010. Available at: https://dhsprogram.com/pubs/
pdf/MIS7/MIS7.pdf (Accessed 6 February 2017).
E.M. Teshome et al. Contemporary Clinical Trials Communications 7 (2017) 1–10
9
[14] M.N. Mwangi, J.M. Roth, M.R. Smit, L. Trijsburg, A.M. Mwangi, A.Y. Demir, et al.,
Eﬀect of daily antenatal iron supplementation on Plasmodium infection in Kenyan
women: a randomized clinical trial, JAMA 314 (10) (2015) 1009–1020.
[15] O.G. Munyekenye, A.K. Githeko, G. Zhou, E. Mushinzimana, N. Minakawa, G. Yan,
Plasmodium falciparum spatial analysis, western Kenya highlands, Emerg. Infect.
Dis. 11 (10) (2005) 1571–1577.
[16] J.R. Verani, B. Abudho, S.P. Montgomery, P.N. Mwinzi, H.L. Shane, S.E. Butler,
et al., Schistosomiasis among young children in Usoma, Kenya, Am. J. Trop. Med.
Hyg. 84 (5) (2011) 787–791.
[17] S. Brooker, N. Peshu, P. Warn, M. Mosobo, H.L. Guyatt, K. Marsh, et al., The
epidemiology of hookworm infection and its contribution to anaemia among pre-
school children on the Kenya coast, Trans. R. Soc. Trop. Med. Hyg. 93 (3) (1999)
240–246.
[18] M. Albonico, H. Allen, L. Chitsulo, D. Engels, A.F. Gabrielli, L. Savioli, Controlling
soil-transmitted helminthiasis in pre-school-age children through preventive che-
motherapy, PLoS Negl. Trop. Dis. 2 (3) (2008) e126.
[19] R.B. D'Agostino, J.M. Massaro, L.M. Sullivan, Non-inferiority trials: design concepts
and issues – the encounters of academic consultants in statistics, Stat. Med. 22 (2)
(2003) 169–186.
[20] J. Schumi, J.T. Wittes, Through the looking glass: understanding non-inferiority,
Trials 12 (2011) 106.
[21] A. Neuberger, J. Okebe, D. Yahav, M. Paul, Oral iron supplements for children in
malaria-endemic areas, Cochrane Database Syst. Rev. 2 (2016) CD006589.
[22] J. Hastka, J. Lasserre, A. Schwarzbeck, M. Strauch, R. Hehlmann, Washing
erythrocytes to remove interferents in measurements of zinc protoporphyrin by
front-face hematoﬂuorometry, Clin. Chem. 38 (11) (1992) 2184–2189.
[23] Preventive chemotherapy in human helminthiasis. Coordinated Use of
Antihelminthic Drugs in Control Interventions: a Manual for Health Professionals
and Programme Managers, World Health Organization, Geneva, Switzerland, 2006
Available at: http://whqlibdoc.who.int/publications/2006/9241547103_eng.pdf
(Accessed 6 February 2017).
[24] H. Verhoef, J. Veenemans, M.N. Mwangi, A.M. Prentice, Safety and beneﬁts of
interventions to increase folate status in malaria-endemic areas, Br. J. Haematol.
(2017), http://dx.doi.org/10.1111/bjh.14618 http://onlinelibrary.wiley.com/doi/
10.1111/bjh.14618/full.
[25] J.A. Cramer, R.H. Mattson, M.L. Prevey, R.D. Scheyer, V.L. Ouellette, How often is
medication taken as prescribed? A novel assessment technique, JAMA 261 (22)
(1989) 3273–3277.
[26] B. Vrijens, J. Urquhart, Patient adherence to prescribed antimicrobial drug dosing
regimens, J. Antimicrob. Chemother. 55 (5) (2005) 616–627.
[27] N.F. Olivieri, D. Matsui, C. Hermann, G. Koren, Compliance assessed by the
medication event monitoring system, Arch. Dis. Child. 66 (12) (1991) 1399–1402.
[28] K.A. Grosset, I. Bone, J.L. Reid, D. Grosset, Measuring therapy adherence in
Parkinson's disease: a comparison of methods, J. Neurol. Neurosurg. Psychiatry 77
(2) (2006) 249–251.
[29] WHO, Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment
of Severity. Vitamin and Mineral Nutrition Information System. Document
Reference WHO/NMH/NHD/MNM/11.1, World Health Organization, Geneva,
Switzerland, 2011 Available: http://www.who.int/entity/vmnis/indicators/
haemoglobin.pdf (Accessed 6 February 2017).
[30] M.T. Makler, C.J. Palmer, A.L. Ager, A review of practical techniques for the
diagnosis of malaria, Ann. Trop. Med. Parasitol. 92 (4) (1998) 419–433.
[31] R. Piper, J. Lebras, L. Wentworth, A. Hunt-Cooke, S. Houzé, P. Chiodini, et al.,
Immunocapture diagnostic assays for malaria using Plasmodium lactate dehydro-
genase (pLDH), Am. J. Trop. Med. Hyg. 60 (1) (1999) 109–118.
[32] A. Moody, Rapid diagnostic tests for malaria parasites, Clin. Microbiol. Rev. 15 (1)
(2002) 66–78.
[33] Serum Ferritin Concentrations for the Assessment of Iron Status and Iron Deﬁciency
in Populations. Vitamin and Mineral Nutrition Information System, World Health
Organization, Geneva, 2011 (WHO/NMH/NHD/MNM/11.2), http://apps.who.int/
iris/bitstream/10665/85843/1/WHO_NMH_NHD_MNM_11.2_eng.pdf?ua=1
(Accessed on 6 February 2017).
[34] K. Abraham, C. Muller, A. Gruters, U. Wahn, F.J. Schweigert, Minimal inﬂamma-
tion, acute phase response and avoidance of misclassiﬁcation of vitamin A and iron
status in infants—importance of a high-sensitivity C-reactive protein (CRP) assay,
Int. J. Vitam. Nutr. Res. 73 (6) (2003) 423–430.
[35] M.A. Ayoya, G.M. Spiekermann-Brouwer, R.J. Stoltzfus, E. Nemeth, J.P. Habicht,
T. Ganz, et al., Alpha 1-acid glycoprotein, hepcidin, C-reactive protein, and serum
ferritin are correlated in anemic schoolchildren with Schistosoma haematobium, Am.
J. Clin. Nutr. 91 (6) (2010) 1784–1790.
[36] Y. Wang, M.C. Kong, Y. Ko, Comparison of three medication adherence measures in
patients taking warfarin, J. Thromb. Thrombolysis 36 (4) (2013) 416–421.
[37] G.J. Knaﬂ, A. Schoenthaler, G. Ogedegbe, Secondary analysis of electronically
monitored medication adherence data for a cohort of hypertensive African-
Americans, Patient Pref. Adherence 6 (2012) 207–219.
[38] S.J. Shalansky, A.R. Levy, A.P. Ignaszewski, Self-reported Morisky score for
identifying nonadherence with cardiovascular medications, Ann. Pharmacother. 38
(9) (2004) 1363–1368.
[39] P.M. Ho, C.L. Bryson, J.S. Rumsfeld, Medication adherence: its importance in
cardiovascular outcomes, Circulation 119 (23) (2009) 3028–3035.
[40] Committee for Proprietary Medicinal Products (CPMP), Points to Consider on
Multiplicity Issues in Clinical Trials. CPMP/EWP/908/99, European Medicine
Agency, London, UK, 2002 Available at: http://www.ema.europa.eu/docs/en_GB/
document_library/Scientiﬁc_guideline/2009/09/WC500003640.pdf (Accessed 6
February 2017).
[41] I. Zongo, P. Milligan, Y.D. Compaore, A.F. Some, B. Greenwood, J. Tarning,
P.J. Rosenthal, C. Sutherland, F. Nosten, J.-B. Ouedraogoa, Randomized noninfer-
iority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyri-
methamine plus amodiaquine for seasonal malaria chemoprevention in Burkina
Faso, Antimicrob. Agents Chemother. 59 (8) (2015) 4387–4396.
[42] H. Verhoef, C.E. West, S.M. Nzyuko, S. de Vogel, R. van der Valk, M.A. Wanga,
A. Kuijsten, J. Veenemans, F.J. Kok, Intermittent administration of iron and
sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised
controlled trial, Lancet 360 (9337) (2002) 908–914.
[43] K.J. Rothman, K.B. Michels, The continuing unethical use of placebo controls, N.
Engl. J. Med. 331 (6) (1994) 394–398.
[44] A. Stang, H.W. Hense, K.H. Jöckel, E.H. Turner, M.R. Tramèr, Is it always unethical
to use a placebo in a clinical trial? PLoS Med. 2 (3) (2005) e72.
[45] K.J. Rothman, Placebo mania: as medical knowledge accumulates, the number of
placebo trials should fall, BMJ 313 (1996) 3–4.
[46] ICH Harmonised tripartite guideline, Choice of control group and related issues in
clinical trials E10, International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2000
Available at: http://www.ich.org/ﬁleadmin/Public_Web_Site/ICH_Products/
Guidelines/Eﬃcacy/E10/Step4/E10_Guideline.pdf (Accessed 6 February 2017).
[47] H. McQuay, A. Moore, Placebo mania: placebo are essential when extent and
variability of placebo response are unknown, BMJ 313 (1996) 1008.
[48] S. Senn, Ethical considerations concerning treatment allocation in drug develop-
ment trials, Stat. Methods Med. Res. 11 (5) (2002) 403–411.
[49] Dmitrienko A, Wiens B. Branching tests in clinical trials with multiple objectives.
Available at: http://www.amstat.org/meetings/fdaworkshop/presentations/2005/
G5_Dmitrienko_Multiplicity.pdf (accessed 6 February 2017).
[50] K.F. Schulz, D.A. Grimes, Multiplicity in randomised trials I: endpoints and
treatments, Lancet 365 (9470) (2005) 1591–1595.
[51] D.G. Altman, J.M. Bland, Absence of evidence is no evidence of absence, BMJ 311
(7003) (1995) 485.
[52] J.A. Sterne, G. Smith Davey, Sifting the evidence—what's wrong with signiﬁcance
tests? BMJ 322 (7280) (2001) 226–231.
E.M. Teshome et al. Contemporary Clinical Trials Communications 7 (2017) 1–10
10
